Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mGluR5
Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
1. A compound having a structure represented by a formula:
wherein Q is selected from N and CR 5 ;
wherein R 5 , when present, is selected from hydrogen, halogen, —CN, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, —OR 30 , —NR 31a R 31b , —SO 2 R 32 , and —(C═O)R 33 ;
wherein R 30 , when present, is selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl;
wherein each of R 31a and R 31b , when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl; or wherein R 31a and R 31b , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 3- to 6-membered heterocycle;
wherein R 32 , when present, is selected from C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —NR 34a R 34b ;
wherein each of R 34a and R 34b , when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl; or wherein R 34a and R 34b , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 3- to 6-membered heterocycle;
wherein R 33 , when present, is selected from C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —NR 35a R 35b ;
wherein each of R 35a and R 35b , when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl; or wherein R 35a and R 35b , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 3- to 6-membered heterocycle;
wherein each of Z 1 and Z 2 is independently selected from N and CR 6 , provided that Z 1 and Z 2 are not simultaneously N;
wherein each of R 6 , when present, is independently selected from hydrogen, halogen, —CN, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, —OR 40 , —NR 41a R 41b , —SO 2 R 42 , and —(C═O)R 43 ;
wherein R 40 , when present, is selected from hydrogen, C1-C3 alkyl,C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl;
wherein each of R 41a and R 41b , when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl; or wherein R 41a and R 41b , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 3- to 6-membered heterocycle;
wherein R 42 , when present, is selected from C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —NR 44a R 44b ;
wherein each of R 44a and R 44b , when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl; or wherein R 44a and R 44b , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 3- to 6-membered heterocycle;
wherein R 43 , when present, is selected from C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —NR 45a R 45b ;
wherein each of R 45a and R 45b , when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl; or wherein R 45a and R 45b , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 3- to 6-membered heterocycle;
wherein R 1 is heteroaryl substituted with 0, 1, 2, or 3 groups independently selected from deuterium, halogen, —CN, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, —OR 60 , —NR 61a R 61b , —SO 2 R 62 , and —(C═O)R 63 ;
wherein each occurrence of R 60 , when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl;
wherein each occurrence of each of R 61a and R 61b , when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl; or wherein R 61a and R 61b , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 3- to 6-membered heterocycle;
wherein each occurrence of R 62 , when present, is independently selected from C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —NR 64a R 64b ;
wherein each occurrence of each of R 64a and R 64b , when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl; or wherein R 64a and R 64b , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 3- to 6-membered heterocycle;
wherein each occurrence of R 63 , when present, is independently from C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —NR 65a R 65b ;
wherein each occurrence of each of R 65a and R 65b , when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl; or wherein R 65a and R 65b , when present, are optionally covalently bonded and, together with nitrogen atom to which they are attached, comprise a 3- to 6-membered heterocycle;
wherein R 2 is selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl;
wherein each of R 3a , R 3b , R 3c , and R 3d , is independently selected from hydrogen and fluoro;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein the compound exhibits partial or total inhibition of mGluR5 response to glutamate as a decrease in response to non-maximal concentrations of glutamate in human embryonic kidney cells transfected with rat mGluR5 in the presence of the compound, compared to the response to glutamate in the absence of the compound.
3. The compound of claim 2 , wherein the compound exhibits partial inhibition of mGluR5 response.
4. The compound of claim 2 , wherein the compound exhibits total inhibition of mGluR5 response.
5. The compound of claim 1 , wherein R 2 is hydrogen.
6. The compound of claim 1 , wherein each of R 3a , R 3b , R 3c , and R 3d is hydrogen.
7. The compound of claim 1 , having a structure represented by a formula:
wherein each of R 70a , R 70b , R 70c , and R 70d is independently selected from hydrogen, halogen, —CN, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, —OR 40 , —NR 41a R 41b , —SO 2 R 42 , and —(C═O)R 43 , provided that at least one of R 70a , R 70a , R 70a , and R 70a is hydrogen.
8. The compound of claim 1 , having a structure represented by a formula:
wherein each of R 80a and R 80b is independently selected from hydrogen, halogen, —CN, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, —OR 40 , —NR 41a R 41b , —SO 2 R 42 , and —(C═O)R 43 .
9. A method for the treatment of a neurological and/or phychiatric disorder associated with glutamate dysfunction in a mammal wherein the disorder is selected from autism spectrum disorder, depression, stroke, head trauma, dementia, Alzheimer's disease, Huntington's Chorea, amyotrophic lateral sclerosis, idiopathic Parkinson's disease, drug induced Parkinson's disease, migraine, addictive behavior, withdrawal from addictive substances, anxiety, mood disorder, and tardive dyskinesia, the method comprising the step of administering to the mammal a therapeutically effective amount of a compound having a structure represented by a formula:
wherein Q is selected from N and CR 5 ;
wherein R 5 , when present, is selected from hydrogen, halogen, —CN, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, —OR 30 , —NR 31a R 31b , —SO 2 R 32 , and —(C═O)R 33 ;
wherein R 30 , when present, is selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl;
wherein each of R 31a and R 31b ), when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl; or wherein R 31a and R 31b , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 3- to 6-membered heterocycle;
wherein R 32 , when present, is selected from C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —NR 34a R 34b ;
wherein each of R 34a and R 34b , when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl; or wherein R 34a and R 34b , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 3- to 6-membered heterocycle;
wherein R 33 , when present, is selected from C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —NR 35a R 35b ;
wherein each of R 35a and R 35b , when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl; or wherein R 35a and R 35b , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 3- to 6-membered heterocycle;
wherein each of Z 1 and Z 2 is independently selected from N and CR 6 , provided that Z 1 and Z 2 are not simultaneously N;
wherein each of R 6 , when present, is independently selected from hydrogen, halogen, —CN, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, —OR 40 , —NR 41a R 41b , —SO 2 R 42 , and —(C═O)R 43 ;
wherein R 40 , when present, is selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl;
wherein each of R 41a and R 41b , when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl; or wherein R 41a and R 41b , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 3- to 6-membered heterocycle;
wherein R 42 , when present, is selected from C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —NR 44a R 44b ;
wherein each of R 44a and R 44b , when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl; or wherein R 44a and R 44b , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 3- to 6-membered heterocycle;
wherein R 43 , when present, is selected from C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —NR 45a R 45b ;
wherein each of R 45a and R 45b , when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl; or wherein R 45a and R 45b , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 3- to 6-membered heterocycle;
wherein R 1 is heteroaryl substituted with 0, 1, 2, or 3 groups independently selected from deuterium, halogen, —CN, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, —OR 60 , —NR 61a R 61b , —SO 2 R 62 , and —(C═O)R 63 ;
wherein each occurrence of R 60 , when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl;
wherein each occurrence of each of R 61a and R 61b , when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl; or wherein R 61a and R 61b , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 3- to 6-membered heterocycle;
wherein each occurrence of R 62 , when present, is independently selected from C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —NR 64a R 64b ;
wherein each occurrence of each of R 64a and R 64b , when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl; or wherein R 64a and R 64b , when present, are optionally covalently bonded and, together with the nitrogen atom to which they are attached, comprise a 3- to 6-membered heterocycle;
wherein each occurrence of R 63 , when present, is independently from C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —NR 65a R 65b ;
wherein each occurrence of each of R 65a and R 65b , when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl; or wherein R 65a and R 65b , when present, are optionally covalently bonded and, together with nitrogen atom to which they are attached, comprise a 3- to 6-membered heterocycle;
wherein R 2 is selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl;
wherein each of R 3a , R 3b , R 3c , and R 3d , is independently selected from hydrogen and fluoro:
or a pharmaceutically acceptable salt thereof.
10. The method of claim 9 , wherein the mammal is a human.
11. The method of claim 9 , wherein the disorder is an autism spectrum disorder.
12. The method of claim 9 , wherein the disorder is depression.
13. The method of claim 9 , wherein the disorder is Parkinson's disease.
14. The method of claim 9 , wherein the compound has a structure represented by a formula:
wherein each of R 70a , R 70b , R 70c , and R 70d is independently selected from hydrogen, halogen, —CN, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, —OR 40 , —NR 41a R 41b ,—SO 2 R 42 , and —(C═O)R 43 , provided that at least one of R 70a , R 70a , R 70a , and R 70a is hydrogen.
15. The method of claim 14 , wherein the compound is selected from:
16. The compound of claim 7 , having a structure represented by a formula:
17. The compound of claim 7 , having a structure represented by a formula:
18. The compound of claim 7 , having a structure represented by a formula: